# US 2025/0134969 A1 · Biosynthetic hemostat and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0134969 A1
- Document ID: US20250134969A1
- Status: Published application
- Kind: A1
- Application number: 18/835,102
- Filed: 2023-02-02
- Published: 2025-05-01
- Earliest claimed: 2022-02-02
- Assignees: Case Western Reserve University
- Applicants: Case Western Reserve University
- Inventors: Anirban Sen Gupta; Aditya Girish
- Web page: https://patentgrep.com/patent/US20250134969A1

## CPC

- A61K 38/4833: {Thrombin (3.4.21.5)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/363: {Fibrinogen}
- A61K 38/37: Factors VIII
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6911: {the form being a liposome}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C12N 9/6429: {Thrombin (3.4.21.5)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A biosynthetic hemostat includes a plurality of biocompatible flexible nanoparticles wherein each nanoparticle includes a shell that defines an outer surface of the nanoparticle and a core, which is loaded with thrombin, and a plurality of von Willebrand factor-binding peptides (VBPs) and collagen-binding peptides (CBPs) that are linked to the shell and extend from the outer surface.

## Claims

### Claim 1

A biosynthetic hemostat comprising:
a biocompatible flexible nanoparticle that includes a shell that defines an outer surface of the nanoparticle and a core, which is loaded with thrombin, and a plurality of von Willebrand factor-binding peptides (VBPs) and collagen-binding peptides (CBPs) that are linked to the shell and extend from the outer surface, wherein the nanoparticle is configured to adhere to a vascular surface, vascular disease site and/or vascular injury site with exposed von Willebrand factor (vWF) and collagen, shield the loaded thrombin in circulation to avoid rapid inhibition or systemic thrombotic risk, and release the loaded thrombin at the vascular surface, vascular disease site and/or vascular injury site by diffusion from the nanoparticle and/or enzyme triggered degradation of the nanoparticle.

### Claim 2 (depends on 1)

The hemostat of claim 1, wherein the nanoparticle binds to the vascular surface, vascular disease site and/or vascular injury site under a hemodynamic shear environment.

### Claim 3 (depends on 1)

The hemostat of claim 1, wherein the enzyme that triggers degradation of the nanoparticle is substantially unique or specific to the vascular disease site and/or vascular injury site and/or has a higher concentration or activity at the vascular disease site and/or vascular injury site compared to other cells, tissues, and/or disease sites in the subject.

### Claim 4 (depends on 1)

The hemostat of claim 1, wherein the shell of the nanoparticle includes at least one phospholipid and the enzyme includes at least one phospholipase that triggers phospholipase degradation of the at least on phospholipid and release of the thrombin.

### Claim 5 (depends on 1)

The hemostat of claim 1, wherein the nanoparticle has a diameter of about 50 nm to about 5 μm.

### Claim 6 (depends on 1)

The hemostat of claim 1, wherein the nanoparticle is a liposome.

### Claim 7 (depends on 6)

The hemostat of claim 6, wherein the liposome includes a plurality of phospholipids and optionally cholesterol to define a lipid membrane.

### Claim 8 (depends on 7)

The hemostat of claim 7, wherein the phospholipids include ate least one of distearoylphosphatidylserine (DSPS), distearoylphosphatidylcholine dipalmitoylphosphatidylcholine (DSPC), dibehenoylglycerophosphocoline (DBPC), distearoylphosphatidylcholine (DSPC), diarachidonylphosphatidylcholine (DAPC), dioleoylphosphatidylethanolamine (DOPE), dipalmitoylphosphatidylethanolamine (DPPE), and distearoylphosphatidylethanolamine (DSPE); dipalmitoylphosphatidic acid (DPPA), or polyethylene glycol (PEG) functionalized lipids thereof.

### Claim 9 (depends on 7)

The hemostat of claim 7, wherein the VBPs and CBPs are conjugated to the phospholipids with PEG linkers.

### Claim 10 (depends on 9)

The hemostat of claim 9, wherein the VBP and CBP conjugated phospholipids comprise about 1 mole % to about 10 mole %, of the total lipid composition of the liposome.

### Claim 11 (depends on 6)

The hemostat of claim 6, wherein the liposome comprises DSPC, DSPE conjugated to VBP with PEG (DSPE-PEG-VBP), DSPE conjugated to CBP with PEG (DSPE-PEG-CBP), and cholesterol.

### Claim 12 (depends on 1)

The hemostat of claim 1, wherein the VBPs and CBPs are spatially or topographically arranged on the outer surface such that the VBPs and CBPs do not spatially mask each other and the nanoparticle is able to adhere to the vascular surface, vascular disease site, and/or vascular injury site with exposed vWF and collagen and promote arrest and aggregation of active platelets onto sites of the nanoparticle adhesion.

### Claim 13 (depends on 1)

The hemostat of claim 1, wherein the nanoparticle has shape, size and elastic modulus that facilitates margination to a vascular injury site upon administration to vasculature of a subject.

### Claim 14 (depends on 1)

The hemostat of claim 1, the VBPs have an amino acid sequence of SEQ ID NO: 1 and the CBPs have an amino acid sequence of SEQ ID NO: 2.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The hemostat of claim 1, wherein the nanoparticle further includes a plurality of fibrinogen mimetic peptides (FMPs) that bind to GPIb-IIIa, endothelial cell targeting peptides, and/or platelet targeting peptides that are linked to the shell and extend from the outer surface.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The hemostat of claim 1, comprising a plurality of the nanoparticles, wherein upon administration to a subject the hemostat provides vascular injury-site targeted delivery of thrombin.

### Claim 19 (depends on 18)

The hemostat of claim 18, wherein the amount of thrombin delivered to the vascular injury site in the subject by the hemostat is an amount effective to augment hemostasis in the subject.

### Claim 20 (depends on 18)

The hemostat of claim 18, wherein the plurality of nanoparticles are further loaded with at least one of a platelet agonist, antifibrinolytic, coagulation factor, or prothrombin.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A method treating at least one of a non-compressible and/or uncontrolled hemorrhage, trauma-induced coagulopathy, congenital, disease associated, or drug induced hemostatic dysfunction, or systemic bleeding dysfunction including polytrauma, internal bleeding, platelet and coagulation factor defects in a subject in need thereof, the method comprising:
administering to the subject a therapeutically effective amount of the hemostat of claim 1.

### Claim at position 23

23-30. (canceled)

### Claim 31 (depends on 1)

A kit comprising the biosynthetic hemostat of claim 1 and optionally fibrinogen and calcium, wherein biosynthetic hemostat and optional fibrinogen if present are stored in separate compartments.

### Claim 32

(canceled)
